Vagal nerve stimulation releases vasoactive intestinal peptide which significantly increases coronary artery blood flow

Cardiovascular Research

Volumn 40, Issue 1, 1998, Pages 45-55

  Feliciano, Lillybeth ^a   Henning, Robert J ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Coronary artery blood flow; Mongrel dog; Neural regulation; Nitroglycerin; Non cholinergic non adrenergic nerve stimulation; Vasoactive intestinal peptide

Indexed keywords

GLYCERYL TRINITRATE; VASOACTIVE INTESTINAL POLYPEPTIDE;

AORTA PRESSURE; ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; ELECTROCARDIOGRAM; HEART MUSCLE RELAXATION; HEART VENTRICLE CONTRACTILITY; HEART VENTRICLE PRESSURE; HORMONE ACTION; HORMONE RELEASE; PRIORITY JOURNAL; VAGUS NERVE STIMULATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ATROPINE; CARDIAC PACING, ARTIFICIAL; CORONARY CIRCULATION; DOGS; ELECTRIC STIMULATION; FEMALE; HORMONE ANTAGONISTS; MALE; MUSCARINIC ANTAGONISTS; NITROGLYCERIN; PROPRANOLOL; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; VAGUS NERVE; VASOACTIVE INTESTINAL PEPTIDE; VASODILATOR AGENTS;

EID: 0032189612     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00122-9     Document Type: Article

References (50)

1. [1] Forssman WG, Triepel J, Daffner C, et al. Vasoactive intestinal peptide in the heart. Ann New York Acad Sci 1988;527:405-420.
2. [2] Lundberg JM, Franco-Cereceda A, Lacroix JS, et al. Release of vasoactive peptides from autonomic and sensory nerves. Blood Vessels 1991;28(1-3):27-34.
3. [3] Accili EA, Buchan AMJ, Kwok YN, et al. Presence and actions of vasoactive intestinal peptide in the isolated rabbit heart. Can J Physiol Pharmacol 1995;73(1):134-139.
4. [4] Anderson FL, Wynn JR, Kimball J, et al. Vasoactive intestinal peptide in canine hearts:effect of total cardiac denervation. Am J Physiol 1992;262:H598-H602.
5. [5] Brum JM, Bove AA, Sufan Q, et al. Action and localization of vasoactive intestinal peptide in the coronary circulation: evidence for nonadrenergic, noncholinergic coronary regulation. J Am Coll Cardiol 1986;7(20):406-413.
6. [6] Della NG, Papka RE, Furness JB, et al. Vasoactive intestinal peptide-like immunoreactivity in nerves associated with the cardiovascular system of guinea-pigs. Neuroscience 1983;9(3):605-619.
7. [7] Gulbenkian S, Opgaard OS, Ekman R, et al. Peptidergic innervation of human epicardial coronary arteries. Circ Res 1993;73(3):579-588.
8. [8] Weihe E, Reinecke M. Peptidergic innervation of the mammalian sinus nodes: Vasoactive intestinal polypeptide, neurotensin, substance P. Neurosci Lett 1981;26(3):283-288.
9. [9] Wharton J, Gulbenkian S. Peptides in the mammalian cardiovascular system. Experientia 1989;56:292-316.
10. [10] Lundberg JM. Evidence for coexistence of vasoactive intestinal peptide (VIP) and acetylcholine in neurons of cat exocrine glands: Morphological, biochemical and functional studies. Acta Physiol Scand 1981;496:1-57.
11. [11] Lundberg JM, Hökfelt T. Multiple co-existence of peptides and classical transmitters in peripheral autonomic and sensory neurons: Functional and pharmacological implications. Prog Brain Res 1986;68:241-262.
12. [12] Henning RJ. Vagal stimulation during muscarinic and beta-adrenergic blockade increases atrial contractility and heart rate. J Auton Nerv Syst 1992;40(2):121-129.
13. [13] Henning RJ, Feliciano L, Coers CM. Vagal nerve stimulation increases right ventricular contraction and relaxation and heart rate. Cardiovas Res 1996;32(5):846-853.
14. [14] Hill MRS, Wallick DW, Mongeon LR, et al. Vasoactive intestinal polypeptide antagonists attenuate vagally induced tachycardia in the anesthetized dog. Am J Physiol 1995;269:H1467-H1472.
15. [15] Grider JR, Rivier J. Vasoactive intestinal peptide (VIP) as transmitter of inhibitory motor neurons of the gut: Evidence from the use of selective VIP antagonists and VIP antiserum. J Pharmacol Exp Ther 1990;253(2):738-742.
16. 17)VIP. Pflugers Arch 1989;414(2):222-227.
17. 17]VIP. Am J Physiol 1986;250:G553-G557.
18. [18] Shvilkin A, Danilo P, Chevalier P, et al. Vagal release of vasoactive intestinal peptide can promote vagotonic tachycardia in the isolated innervated rat heart. Cardiovas Res 1994;28:1769-1773.
19. [19] Hill MR, Wallick DW, Martin PJ, et al. Frequency dependence of vasoactive intestinal polypeptide release and vagally induced tachycardia in the canine heart. J Auton Nerv Syst 1993;43:117-122.
20. [20] Hoover DB. Effects of guinea pig vasoactive intestinal peptide on the isolated perfused guinea pig heart. Peptides 1989;10(2):343-347.
21. [21] Itoh H, Lederis KP, Rorstad OP. Relaxation of isolated bovine coronary arteries by vasoactive intestinal peptide. Eur J Pharmacol 1990;181(3):199-205.
22. [22] Jones JHC, Kuo L, Davis MJ, et al. In vivo and in vitro vasoactive reactions of coronary arteriolar microvessels to nitroglycerin. Am J Physiol 1996;271:H461-H468.
23. [23] Anderson FL, Kralios AC, Hershberger R, et al. Effect of vasoactive intestinal peptide on myocardial contractility and coronary blood flow in the dog: Comparison with isoproterenol and forskolin. J Cardiovasc Pharmacol 1988;12(3):365-371.
24. [24] Macho P, Vatner S. Effects of nitroglycerin and nitroprusside on large and small coronary vessels in conscious dogs. Circulation 1981;64:1101-1107.
25. [25] Zhang J, Somers M, Cobb F. Heterogeneous effects of nitroglycerin on the conductance and resistance coronary arterial vasculature. Am J Physiol 1993;264:H1960-H1968.
26. [26] Bahler RC, Martin P. Effects of loading conditions and inotropic state on rapid filling phase of left ventricle. Am J Physiol 1985;248:H523-H533.
27. [27] Rigel D. Effects of neuropeptides on heart rates in dogs: comparison of VIP, PHI, NPY, CGRP, and NT. Am J Physiol 1988;255:H311-H317.
28. [28] Hill MRS, Wallick DW, Martin PJ, et al. Effects of repetitive vagal stimulation on heart rate and on cardiac vasoactive polypeptide efflux. Am J Physiol 1995;26:H1939-H1946.
29. [29] Scheel KW, Ingram LA, Gordey RL. Relationship of coronary flow and perfusion territory in dogs. Am J Physiol 1982;243(5):H738-H747.
30. [30] Sokall RR, Rohlf FJ. Biometry: The principles and practices of statistics in biological research. San Francisco: WH. Freeman, 1969.
31. [31] Xenopoulos NP, Applegate RJ. Effects of vasoactive intestinal peptide on myocardial performance. Am J Physiol 1994;266:H399-H405.
32. 17]VIP in the awake dog. Peptides 1991;12:989-993.
33. [33] Anderson FL, Kralios AC, Reid B. Release of vasoactive intestinal peptide and neuropeptide Y from canine heart. Am J Physiol 1993;265:H959-H965.
34. [34] Christophe J, Waelbroeck M, Chatelain P, et al. Heart receptors for VIP, PHI and Secretin are able to activate adenylate cyclase and to mediate inotropic and chronotropic effects. Species variations and physiopathology. Peptides 1984;5(2):341-353.
35. [35] Huang M, Rorstad OP. VIP receptors in mesenteric and coronary arteries: A radioligand binding study. Peptides 1987;8(3):477-485.
36. [36] Reimer KA, Jennings RB. Myocardial ischemia, hypoxia and infarction. In: Fozzard HA, Jennings, RB, Haber E, Katz AM, Morgan HE, editors. The Heart and Cardiovascular System. New York: Raven Press, 1992:1884-1885.
37. [37] Popma JJ, Smitherman TC, Bedotto JB, et al. Direct coronary vasodilation induced by intracoronary vasoactive intestinal peptide. J Cardiovasc Pharmacol 1990;16(6):1000-1006.
38. [38] Henning RJ, Cheng J, Levy MN. Vagal stimulation decreases rate of left ventricular relaxation. Am J Physiol 1989;256:H428-H433.
39. [39] Beny JL, Brunet H, Huggel H. Effect of mechanical stimulation, substance P and vasoactive intestinal polypeptide on the electrical and mechanical activities of circular smooth muscles from pig coronary arteries contracted with acetylcholine: Role of endothelium. Pharmacology 1986;33(2):61-68.
40. [40] Ganz P, Sandrock AW, Landis SC, et al. Vasoactive intestinal peptide:vasodilation and cyclic AMP generation. Am J Physiol 1986;250:H755-H760.
41. [41] Kobayashi H, Uezono Y, Ueno S, et al. Pituitary adenylate cyclase-activating polypeptides (PACAPs) increase cAMP in rat cerebral microvessels. Brain Res 1994;647(1):145-147.
42. [42] Lundberg JM, Anggard A, Fahrenkrug J. Complementary role of vasoactive intestinal polypeptide (VIP) and acetylcholine for cat submandibular gland blood flow and secretion I. VIP release. Acta Physiol Scand 1981;113(3):317-327.
43. [43] Fahrenkrug J, Ottesen B. Nervous release of vasoactive intestinal polypeptide from the feline uterus: pharmacological characteristics. J Physiol 1982;331:451-460.
44. [44] Heistad DD, Marcus ML, Said SI, et al. Effects of acetylcholine and vasoactive intestinal polypeptide on cerebral blood flow. Am J Physiol 1980;239(1):H73-H80.
45. [45] Nilsson SFE, Bill A. Vasoactive intestinal polypeptide (VIP): Effects in the eye and on regional blood flows. Acta Physiol Scand 1984;121(4):385-392.
46. [46] Grider JR, Makhlouf GM. Prejunctional inhibition of vasoactive intestinal peptide release. Am J Physiol 1987;253:G7-G12.
47. [47] Rand MJ, Majewski H, Story DF. Modulation of neuroeffector transmission. In: Antonaccio MJ, editor. Cardiovascular Pharmacology. New York: Raven Press, 1990:229-292.
48. [48] Corr PB, Yamad KA, Witkowski FX. Mechanisms controlling cardiac autonomic function and their relation to arrhythmogenesis. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, editors. The Heart and Cardiovascular System. New York: Raven Press, 1986:1352-1353.
49. [49] Kunze DL. Reflex discharge patterns of cardiac vagal fibers. J Physiol (Lond) 1972;222:1.
50. [50] Prystowsky EN, Zipes DP. Postvagal tachycardia. Am J Cardiol 1985;55:995-999.